Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
December 12, 2024 07:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics Approach
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
November 21, 2024 07:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
November 19, 2024 16:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
November 04, 2024 07:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656,...
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
November 01, 2024 16:45 ET
|
Conduit Pharmaceuticals
SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial...
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024 08:00 ET
|
Conduit Pharmaceuticals
SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright 26th...
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
August 12, 2024 07:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
August 08, 2024 06:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
July 16, 2024 07:30 ET
|
Conduit Pharmaceuticals
SAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the approval of a...
Conduit Pharmaceuticals to Join Russell 3000® Index
June 13, 2024 08:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals to Join Russell 3000® Index